Last reviewed · How we verify

NCT04861493

Cathelicidin LL-37 Levels in the GCF and the Saliva of Smokers and Non-smokers With Stage III,IV Periodontitis

Completed Last updated 27 April 2021
What this trial tests

trial in Smoking Reduction in 60 participants. Completed in 15 April 2021.

Timeline
23 February 2021
Primary endpoint
23 February 2021
15 April 2021

Quick facts

Lead sponsorCairo University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment60
Start date23 February 2021
Primary completion23 February 2021
Estimated completion15 April 2021
Sites1 location across Egypt

Conditions studied

Sponsor

Cairo University

Who can join

Eligibility, any sex, with Smoking Reduction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Periodontitis is considered an inflammatory disease that results in the disruption of oral hemeostasis and is associated with the presence of dental plaque influenced by genetic and environmental factors. It is well-establised that smokers have an increased severity of periodontal disease,a higher prevalance of tooth loss and total edentulism.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Cathelicidins: Opportunities and Challenges in Skin Therapeutics and Clinical Translation.
    Dzurová L, Holásková E, Pospíšilová H, Schneider Rauber G, et al · · 2024 · cited 8× · PMID 39858288 · DOI 10.3390/antibiotics14010001

Verify or expand the search:

Other recruiting trials for Smoking Reduction

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04861493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing